AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. JAGX
  4. [Form 4] Jaguar Health, Inc. Insider Trading Activity

[Form 4] Jaguar Health, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Lisa A. Conte, CEO, President and Director of Jaguar Health (JAGX), reported significant changes in derivative securities holdings on June 24, 2025. The transactions involved restructuring of convertible debt and issuance of new warrants:

  • Disposed of original 6% convertible promissory note (9,000 shares at $5.555 conversion price) maturing June 30, 2025
  • Acquired new 6% convertible promissory note (9,462 shares at $5.555 conversion price) maturing January 30, 2026
  • Received warrant to purchase 18,262 common shares at $2.70 exercise price, expiring December 24, 2026

The exchange was part of an issuer exchange offer, extending the maturity of the convertible debt by 7 months. The warrant was issued as an inducement and becomes exercisable upon stockholder approval. The transaction indicates potential debt restructuring efforts by the company while providing the executive with additional equity participation opportunities.

Lisa A. Conte, CEO, Presidente e Direttrice di Jaguar Health (JAGX), ha comunicato il 24 giugno 2025 modifiche significative nelle sue partecipazioni in titoli derivati. Le operazioni hanno riguardato la ristrutturazione di debito convertibile e l'emissione di nuovi warrant:

  • Disposto il rimborso della nota convertibile originale al 6% (9.000 azioni a un prezzo di conversione di 5,555 $) con scadenza il 30 giugno 2025
  • Acquisita una nuova nota convertibile al 6% (9.462 azioni a un prezzo di conversione di 5,555 $) con scadenza il 30 gennaio 2026
  • Ricevuto un warrant per l'acquisto di 18.262 azioni ordinarie a un prezzo di esercizio di 2,70 $, con scadenza il 24 dicembre 2026

Lo scambio faceva parte di un'offerta di scambio dell'emittente, estendendo la scadenza del debito convertibile di 7 mesi. Il warrant 猫 stato emesso come incentivo e diventa esercitabile previa approvazione degli azionisti. L'operazione suggerisce possibili sforzi di ristrutturazione del debito da parte della societ脿, offrendo al contempo all'esecutivo ulteriori opportunit脿 di partecipazione azionaria.

Lisa A. Conte, CEO, Presidenta y Directora de Jaguar Health (JAGX), inform贸 cambios significativos en la tenencia de valores derivados el 24 de junio de 2025. Las transacciones involucraron la reestructuraci贸n de deuda convertible y la emisi贸n de nuevos warrants:

  • Disposici贸n de la nota promisoria convertible original al 6% (9,000 acciones a un precio de conversi贸n de $5.555) con vencimiento el 30 de junio de 2025
  • Adquisici贸n de una nueva nota promisoria convertible al 6% (9,462 acciones a un precio de conversi贸n de $5.555) con vencimiento el 30 de enero de 2026
  • Recepci贸n de un warrant para comprar 18,262 acciones comunes a un precio de ejercicio de $2.70, con vencimiento el 24 de diciembre de 2026

El intercambio fue parte de una oferta de intercambio del emisor, extendiendo el vencimiento de la deuda convertible por 7 meses. El warrant fue emitido como incentivo y se vuelve ejercitable tras la aprobaci贸n de los accionistas. La transacci贸n indica posibles esfuerzos de reestructuraci贸n de deuda por parte de la empresa, al tiempo que brinda al ejecutivo oportunidades adicionales de participaci贸n accionaria.

Lisa A. Conte, Jaguar Health(JAGX)鞚� CEO, 靷灔 氚� 鞚挫偓電� 2025雲� 6鞗� 24鞚� 韺岇儩 歃濌秾 氤挫湢鞐� 欷戨寑頃� 氤�霃� 靷暛鞚� 氤搓碃頄堨姷雼堧嫟. 鞚措矆 瓯半灅電� 鞝勴櫂 靷眲 鞛惮靹标臣 靸堧鞖� 鞗岆煱韸� 氚滍枆鞚� 韽暔頃╇媹雼�:

  • 鞗愲灅 6% 鞝勴櫂 鞎届啀鞏挫潓(鞝勴櫂 臧�瓴� $5.555鞐� 9,000欤�) 毵岅赴鞚� 2025雲� 6鞗� 30鞚� 觳橂秳
  • 靸堧鞖� 6% 鞝勴櫂 鞎届啀鞏挫潓(鞝勴櫂 臧�瓴� $5.555鞐� 9,462欤�) 毵岅赴鞚� 2026雲� 1鞗� 30鞚� 旆摑
  • 頄夓偓臧�瓴� $2.70, 毵岅赴鞚� 2026雲� 12鞗� 24鞚检澑 18,262欤� 氤错喌欤� 毵れ垬 鞗岆煱韸� 靾橂牴

鞚措矆 甑愴櫂鞚� 氚滍枆靷� 甑愴櫂 鞝滌晥鞚� 鞚茧秬搿�, 鞝勴櫂 靷眲 毵岅赴毳� 7臧滌洈 鞐办灔頃橂姅 臁办箻鞓�鞀惦媹雼�. 鞗岆煱韸鸽姅 鞙犾澑毂呾溂搿� 氚滍枆霅橃棃鞙茧┌ 欤检＜ 鞀轨澑 鞁� 頄夓偓 臧�電ロ暣歆戨媹雼�. 鞚� 瓯半灅電� 須岇偓鞚� 攵�毂� 鞛惮靹� 臧�電レ劚鞚� 鞁滌偓頃橂┌, 瓴届榿歆勳棎瓴� 於旉皜鞝侅澑 欤检嫕 彀胳棳 旮绊殞毳� 鞝滉车頃╇媹雼�.

Lisa A. Conte, PDG, Pr茅sidente et Directrice de Jaguar Health (JAGX), a signal茅 des changements significatifs dans ses d茅tentions de titres d茅riv茅s le 24 juin 2025. Les transactions ont concern茅 la restructuration de dette convertible et l'茅mission de nouveaux warrants :

  • Ali茅nation de la note convertible originale 脿 6 % (9 000 actions au prix de conversion de 5,555 $) arrivant 脿 茅ch茅ance le 30 juin 2025
  • Acquisition d'une nouvelle note convertible 脿 6 % (9 462 actions au prix de conversion de 5,555 $) arrivant 脿 茅ch茅ance le 30 janvier 2026
  • R茅ception d'un warrant d'achat de 18 262 actions ordinaires au prix d'exercice de 2,70 $, expirant le 24 d茅cembre 2026

Cet 茅change faisait partie d'une offre d'茅change de l'茅metteur, prolongeant l'茅ch茅ance de la dette convertible de 7 mois. Le warrant a 茅t茅 茅mis 脿 titre d'incitation et devient exer莽able apr猫s approbation des actionnaires. Cette op茅ration indique des efforts potentiels de restructuration de la dette par la soci茅t茅 tout en offrant 脿 la dirigeante des opportunit茅s suppl茅mentaires de participation au capital.

Lisa A. Conte, CEO, Pr盲sidentin und Direktorin von Jaguar Health (JAGX), meldete am 24. Juni 2025 bedeutende Ver盲nderungen bei den Best盲nden an Derivatwerten. Die Transaktionen betrafen die Umstrukturierung von Wandelanleihen und die Ausgabe neuer Optionsscheine:

  • Ver盲u脽erung der urspr眉nglichen 6% Wandelanleihe (9.000 Aktien zum Wandlungspreis von 5,555 $) mit F盲lligkeit am 30. Juni 2025
  • Erwerb einer neuen 6% Wandelanleihe (9.462 Aktien zum Wandlungspreis von 5,555 $) mit F盲lligkeit am 30. Januar 2026
  • Erhalt eines Warrants zum Kauf von 18.262 Stammaktien zum Aus眉bungspreis von 2,70 $, g眉ltig bis zum 24. Dezember 2026

Der Tausch war Teil eines Emittentenaustauschangebots, das die Laufzeit der Wandelanleihe um 7 Monate verl盲ngerte. Der Warrant wurde als Anreiz ausgegeben und wird mit Zustimmung der Aktion盲re aus眉bbar. Die Transaktion deutet auf m枚gliche Bem眉hungen des Unternehmens zur Schuldenrestrukturierung hin und bietet der F眉hrungskraft zus盲tzliche Beteiligungsm枚glichkeiten am Eigenkapital.

Positive
  • None.
Negative
  • CEO Lisa Conte exchanged existing convertible note for new note with extended maturity and received additional warrants, potentially indicating company's need to restructure short-term debt obligations

Lisa A. Conte, CEO, Presidente e Direttrice di Jaguar Health (JAGX), ha comunicato il 24 giugno 2025 modifiche significative nelle sue partecipazioni in titoli derivati. Le operazioni hanno riguardato la ristrutturazione di debito convertibile e l'emissione di nuovi warrant:

  • Disposto il rimborso della nota convertibile originale al 6% (9.000 azioni a un prezzo di conversione di 5,555 $) con scadenza il 30 giugno 2025
  • Acquisita una nuova nota convertibile al 6% (9.462 azioni a un prezzo di conversione di 5,555 $) con scadenza il 30 gennaio 2026
  • Ricevuto un warrant per l'acquisto di 18.262 azioni ordinarie a un prezzo di esercizio di 2,70 $, con scadenza il 24 dicembre 2026

Lo scambio faceva parte di un'offerta di scambio dell'emittente, estendendo la scadenza del debito convertibile di 7 mesi. Il warrant 猫 stato emesso come incentivo e diventa esercitabile previa approvazione degli azionisti. L'operazione suggerisce possibili sforzi di ristrutturazione del debito da parte della societ脿, offrendo al contempo all'esecutivo ulteriori opportunit脿 di partecipazione azionaria.

Lisa A. Conte, CEO, Presidenta y Directora de Jaguar Health (JAGX), inform贸 cambios significativos en la tenencia de valores derivados el 24 de junio de 2025. Las transacciones involucraron la reestructuraci贸n de deuda convertible y la emisi贸n de nuevos warrants:

  • Disposici贸n de la nota promisoria convertible original al 6% (9,000 acciones a un precio de conversi贸n de $5.555) con vencimiento el 30 de junio de 2025
  • Adquisici贸n de una nueva nota promisoria convertible al 6% (9,462 acciones a un precio de conversi贸n de $5.555) con vencimiento el 30 de enero de 2026
  • Recepci贸n de un warrant para comprar 18,262 acciones comunes a un precio de ejercicio de $2.70, con vencimiento el 24 de diciembre de 2026

El intercambio fue parte de una oferta de intercambio del emisor, extendiendo el vencimiento de la deuda convertible por 7 meses. El warrant fue emitido como incentivo y se vuelve ejercitable tras la aprobaci贸n de los accionistas. La transacci贸n indica posibles esfuerzos de reestructuraci贸n de deuda por parte de la empresa, al tiempo que brinda al ejecutivo oportunidades adicionales de participaci贸n accionaria.

Lisa A. Conte, Jaguar Health(JAGX)鞚� CEO, 靷灔 氚� 鞚挫偓電� 2025雲� 6鞗� 24鞚� 韺岇儩 歃濌秾 氤挫湢鞐� 欷戨寑頃� 氤�霃� 靷暛鞚� 氤搓碃頄堨姷雼堧嫟. 鞚措矆 瓯半灅電� 鞝勴櫂 靷眲 鞛惮靹标臣 靸堧鞖� 鞗岆煱韸� 氚滍枆鞚� 韽暔頃╇媹雼�:

  • 鞗愲灅 6% 鞝勴櫂 鞎届啀鞏挫潓(鞝勴櫂 臧�瓴� $5.555鞐� 9,000欤�) 毵岅赴鞚� 2025雲� 6鞗� 30鞚� 觳橂秳
  • 靸堧鞖� 6% 鞝勴櫂 鞎届啀鞏挫潓(鞝勴櫂 臧�瓴� $5.555鞐� 9,462欤�) 毵岅赴鞚� 2026雲� 1鞗� 30鞚� 旆摑
  • 頄夓偓臧�瓴� $2.70, 毵岅赴鞚� 2026雲� 12鞗� 24鞚检澑 18,262欤� 氤错喌欤� 毵れ垬 鞗岆煱韸� 靾橂牴

鞚措矆 甑愴櫂鞚� 氚滍枆靷� 甑愴櫂 鞝滌晥鞚� 鞚茧秬搿�, 鞝勴櫂 靷眲 毵岅赴毳� 7臧滌洈 鞐办灔頃橂姅 臁办箻鞓�鞀惦媹雼�. 鞗岆煱韸鸽姅 鞙犾澑毂呾溂搿� 氚滍枆霅橃棃鞙茧┌ 欤检＜ 鞀轨澑 鞁� 頄夓偓 臧�電ロ暣歆戨媹雼�. 鞚� 瓯半灅電� 須岇偓鞚� 攵�毂� 鞛惮靹� 臧�電レ劚鞚� 鞁滌偓頃橂┌, 瓴届榿歆勳棎瓴� 於旉皜鞝侅澑 欤检嫕 彀胳棳 旮绊殞毳� 鞝滉车頃╇媹雼�.

Lisa A. Conte, PDG, Pr茅sidente et Directrice de Jaguar Health (JAGX), a signal茅 des changements significatifs dans ses d茅tentions de titres d茅riv茅s le 24 juin 2025. Les transactions ont concern茅 la restructuration de dette convertible et l'茅mission de nouveaux warrants :

  • Ali茅nation de la note convertible originale 脿 6 % (9 000 actions au prix de conversion de 5,555 $) arrivant 脿 茅ch茅ance le 30 juin 2025
  • Acquisition d'une nouvelle note convertible 脿 6 % (9 462 actions au prix de conversion de 5,555 $) arrivant 脿 茅ch茅ance le 30 janvier 2026
  • R茅ception d'un warrant d'achat de 18 262 actions ordinaires au prix d'exercice de 2,70 $, expirant le 24 d茅cembre 2026

Cet 茅change faisait partie d'une offre d'茅change de l'茅metteur, prolongeant l'茅ch茅ance de la dette convertible de 7 mois. Le warrant a 茅t茅 茅mis 脿 titre d'incitation et devient exer莽able apr猫s approbation des actionnaires. Cette op茅ration indique des efforts potentiels de restructuration de la dette par la soci茅t茅 tout en offrant 脿 la dirigeante des opportunit茅s suppl茅mentaires de participation au capital.

Lisa A. Conte, CEO, Pr盲sidentin und Direktorin von Jaguar Health (JAGX), meldete am 24. Juni 2025 bedeutende Ver盲nderungen bei den Best盲nden an Derivatwerten. Die Transaktionen betrafen die Umstrukturierung von Wandelanleihen und die Ausgabe neuer Optionsscheine:

  • Ver盲u脽erung der urspr眉nglichen 6% Wandelanleihe (9.000 Aktien zum Wandlungspreis von 5,555 $) mit F盲lligkeit am 30. Juni 2025
  • Erwerb einer neuen 6% Wandelanleihe (9.462 Aktien zum Wandlungspreis von 5,555 $) mit F盲lligkeit am 30. Januar 2026
  • Erhalt eines Warrants zum Kauf von 18.262 Stammaktien zum Aus眉bungspreis von 2,70 $, g眉ltig bis zum 24. Dezember 2026

Der Tausch war Teil eines Emittentenaustauschangebots, das die Laufzeit der Wandelanleihe um 7 Monate verl盲ngerte. Der Warrant wurde als Anreiz ausgegeben und wird mit Zustimmung der Aktion盲re aus眉bbar. Die Transaktion deutet auf m枚gliche Bem眉hungen des Unternehmens zur Schuldenrestrukturierung hin und bietet der F眉hrungskraft zus盲tzliche Beteiligungsm枚glichkeiten am Eigenkapital.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CONTE LISA A
(Last) (First) (Middle)
C/O JAGUAR HEALTH, INC.
200 PINE STREET, SUITE 400
(Street)
SAN FRANCISCO CA 94104
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Jaguar Health, Inc. [ JAGX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO and President
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Convertible Promissory Note $5.555 06/24/2025 D 9,000 (1) (1) Common Stock 9,000 $50,000(1) 0 D
Convertible Promissory Note $5.555 06/24/2025 A 9,462 (1) (1) Common Stock 9,462 $50,000(1) 9,462 D
Warrant to Purchase Common Stock $2.7 06/24/2025 A 18,262 (2) 12/24/2026 Common Stock 18,262 (2) 9,000 D
Explanation of Responses:
1. The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,462 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.
2. As an inducement to enter into the issuer exchange offer, the reporting person received a warrant (the "Warrant") to purchase up to 18,262 shares of Common Stock with an exercise price of $2.70 per share. The Warrant is exercisable immediately upon receipt of stockholder approval and will expire on the earlier of (i) 18 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.
/s/ Lisa A Conte 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider trading activity occurred at JAGX on June 24, 2025?

CEO and President Lisa A. Conte exchanged her existing 6% convertible promissory note for a new note and received additional warrants. She disposed of a note convertible to 9,000 shares and received a new note convertible to 9,462 shares, plus warrants to purchase 18,262 shares at $2.70 per share.

What is the conversion price of JAGX CEO's new promissory note?

The new 6% convertible promissory note has a conversion price of $5.555 per share, allowing for conversion into 9,462 shares of JAGX common stock.

When do JAGX CEO Lisa Conte's new warrants expire?

The warrants expire on December 24, 2026 (18 months from issuance) or earlier if there is either a fundamental transaction or liquidation event. The warrants become exercisable immediately upon receiving stockholder approval.

What was the maturity date extension for JAGX CEO's convertible note?

Through the exchange, the maturity date was extended from June 30, 2025 (Original Note) to January 30, 2026 (New Note), representing a 7-month extension.

What is the exercise price of the new warrants issued to JAGX's CEO?

The warrants were issued with an exercise price of $2.70 per share for up to 18,262 shares of common stock, given as an inducement for participating in the issuer exchange offer.
Stock JAGX logo
Jaguar Health Inc

NASDAQ:JAGX

JAGX Rankings

#10536 Ranked by Market Cap
N/A Ranked by Dividends
#71 Top Gainer

JAGX Latest News

Jul 10, 2025
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Jul 8, 2025
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca
Jun 30, 2025
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient
Jun 26, 2025
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Jun 25, 2025
Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

JAGX Latest SEC Filings

Jun 30, 2025
[8-K] Jaguar Health, Inc. Reports Material Event
Jun 30, 2025
[EFFECT] Jaguar Health, Inc. SEC Filing
Jun 27, 2025
[424B3] Jaguar Health, Inc. Prospectus Filed Pursuant to Rule 424(b)(3)
Jun 27, 2025
[424B5] Jaguar Health, Inc. Prospectus Supplement (Debt Securities)
Jun 26, 2025
[Form 4] Jaguar Health, Inc. Insider Trading Activity

JAGX Stock Data

3.40M
1.17M
14.81%
1.71%
5.81%
Biotechnology
Pharmaceutical Preparations
United States
SAN FRANCISCO